Galmed Pharmaceuticals (Galmed Pharmaceuticals) Debt-to-EBITDA : -0.01 (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Galmed Pharmaceuticals Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Galmed Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.04 Mil. Galmed Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. Galmed Pharmaceuticals's annualized EBITDA for the quarter that ended in Dec. 2023 was $-8.58 Mil. Galmed Pharmaceuticals's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Galmed Pharmaceuticals's Debt-to-EBITDA or its related term are showing as below:

GLMD' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.02 Med: -0.01 Max: -0.01
Current: -0.01

During the past 12 years, the highest Debt-to-EBITDA Ratio of Galmed Pharmaceuticals was -0.01. The lowest was -0.02. And the median was -0.01.

GLMD's Debt-to-EBITDA is ranked worse than
100% of 274 companies
in the Biotechnology industry
Industry Median: 1.325 vs GLMD: -0.01

Galmed Pharmaceuticals Debt-to-EBITDA Historical Data

The historical data trend for Galmed Pharmaceuticals's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galmed Pharmaceuticals Debt-to-EBITDA Chart

Galmed Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

Get a 7-Day Free Trial

-0.02

-0.01

Galmed Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial															-0.02	-	-	-	-0.01

Competitive Comparison of Galmed Pharmaceuticals's Debt-to-EBITDA

For the Biotechnology subindustry, Galmed Pharmaceuticals's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Galmed Pharmaceuticals's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galmed Pharmaceuticals's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Galmed Pharmaceuticals's Debt-to-EBITDA falls into.

Galmed Pharmaceuticals Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Galmed Pharmaceuticals's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.041	+	0)	/	-7.461
	=	-0.01

Galmed Pharmaceuticals's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.041	+	0)	/	-8.58
	=	-0.00

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.

Galmed Pharmaceuticals (NAS:GLMD) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Galmed Pharmaceuticals Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Galmed Pharmaceuticals's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Galmed Pharmaceuticals (Galmed Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galmed Pharmaceuticals Ltd (NAS:GLMD) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

GPH:Germany

Address

16 Tiomkin Street, Tel Aviv, ISR, 6578317

Website

https://www.galmedpharma.com

Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.